Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.40 |
| ▸ | WNT3A | P56704 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102364 | 0.78 | ALDH1A1 (0.54) | NPC1RAB9ACYP1A2SMN1; SMN2TDP1 | |
| SCHEMBL27619377 | 0.76 | CYP1A2 (0.52) | NPC1RAB9ACYP1A2SMN1; SMN2TDP1 | |
| SCHEMBL28063081 | 0.74 | SMN1; SMN2 (0.63) | NPC1RAB9ASMN1; SMN2TDP1CASP3 | |
| SCHEMBL24117372 | 0.74 | CYP2A6 (0.56) | NPC1RAB9ACYP1A2HPGDALDH1A1 | |
| SCHEMBL12330301 | 0.74 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2TDP1CASP3 | |
| SCHEMBL16205920 | 0.73 | PARP1 (0.49) | CYP1A2SMN1; SMN2 | |
| SCHEMBL23367937 | 0.73 | RAB9A (0.61) | NPC1RAB9ASMN1; SMN2TDP1CASP3 | |
| SCHEMBL12301240 | 0.72 | NPC1 (0.46) | GRM1NPC1RAB9ASMN1; SMN2TDP1 | |
| SCHEMBL10253480 | 0.72 | SMN1; SMN2 (0.60) | NPC1RAB9ASMN1; SMN2TDP1HPGD | |
| SCHEMBL12301237 | 0.72 | CYP1A2 (0.45) | CYP1A2SMN1; SMN2HPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709012-B1 | 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-29 | — | — | EP | disclosed |
| US-20110230491-A1 | 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE | 2011-09-22 | — | — | US | disclosed |
| US-20110230491-A1 | 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | MABIRE DOMINIQUE JEAN-PIERRE | 2011-09-22 | — | — | US | disclosed |
| US-7879857-B2 | such as 6-[2-(dimethylamino)-1-hydroxyethyl]-3-ethyl-1H-quinolin-2-one, useful in enhancing the effectiveness of chemotherapy and radiotherapy | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-7879857-B2 | such as 6-[2-(dimethylamino)-1-hydroxyethyl]-3-ethyl-1H-quinolin-2-one, useful in enhancing the effectiveness of chemotherapy and radiotherapy | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-20070129375-A1 | 6-Substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors | JANSSEN PHARMCEUTICA, NV (BE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129375-A1 | 6-Substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors | JANSSEN PHARMCEUTICA, NV (BE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129375-A1 | 6-Substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors | PARP1, PARP2, PARP3 | GRM1 3544/4885NPC1 3466/4885RAB9A 2155/4885 |
| US-20110230491-A1 | 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | GRM1 3544/4885NPC1 3466/4885RAB9A 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.